Phys Vivas · cardiovascular
Anticoagulation and Antiplatelet Therapy — Viva Defence
Structured DCE viva: defending anticoagulation in an elderly patient with atrial fibrillation, recurrent falls and chronic kidney disease — risk quantification, agent choice, and the probing questions examiners actually ask.
On this page
Study tools
Target exams
Opening statement (SASPOP, delivered aloud)
"Mrs Brooks is an 82-year-old retired teacher with persistent atrial fibrillation and a CHA₂DS₂-VASc score of at least 4, giving her a substantial annual stroke risk — on the background of stage 3 chronic kidney disease and recurrent falls, one injurious. Her anticoagulation was stopped after a fall, converting a managed bleeding risk into an unmanaged stroke risk. Her problems are: cardioembolic stroke risk that is currently untreated; CKD, which constrains agent choice and mandates scheduled renal review; a falls syndrome that needs its own workup and treatment; and a family whose fear of bleeding needs respectful, numerical answering. My goal today is to re-establish safe anticoagulation with the lowest-bleeding agent her kidneys allow, and to treat the falls rather than surrendering to them." [1] [3]
References5ShowHide
- [1]Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls Arch Intern Med, 1999.PMID 10218746
- [2]Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med, 2011.PMID 21870978
- [3]Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest, 2010.PMID 19762550
- [4]Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest, 2010.PMID 20299623
- [5]Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med, 2009.PMID 19717844